Nafarelin

Overview

Nafarelin, marketed as Synarel, is a synthetic analogue of gonadotropin-releasing hormone (GnRH). Unlike depot injections in this class, nafarelin is delivered as an intranasal spray, absorbed through the lining of the nose, which allows self-administration at home under a clinician's direction.

Nafarelin is approved for the management of endometriosis, where lowering estrogen can reduce associated pain and lesion activity, and for central precocious puberty in children, where it suppresses premature sex hormone production. By reducing the hormones that drive these conditions, it aims to ease symptoms or pause early development.

As a GnRH agonist, nafarelin initially stimulates hormone release before producing suppression, the characteristic flare. Its nasal route distinguishes it from the injectable agonists in everyday use.

How it works

GnRH is normally released by the hypothalamus in pulses, prompting the pituitary to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which regulate estrogen and testosterone production.

Nafarelin binds pituitary GnRH receptors. Because it is given regularly rather than in natural pulses, it first stimulates a rise in LH and FSH, producing a temporary increase in sex hormones, the flare. Continued exposure desensitizes and downregulates the receptors, so LH and FSH output falls and sex hormone levels decline substantially.

In endometriosis, the resulting low-estrogen state can reduce the hormonal stimulation of endometrial tissue and ease symptoms. In central precocious puberty, suppression halts the premature activation of the reproductive axis. Because nafarelin is absorbed nasally, consistent administration technique helps maintain reliable hormone suppression. The effect is generally reversible after stopping.

Clinical evidence

Nafarelin has an established role in gynecology and pediatric endocrinology. In endometriosis, it has been studied for relief of pelvic pain and other symptoms, achieving effects through estrogen suppression comparable to other GnRH agonists, with the convenience of a nasal route.

In central precocious puberty, nafarelin has been used and evaluated to suppress the prematurely active reproductive axis, with clinicians monitoring pubertal markers and growth. Its intranasal delivery makes it a practical option for patients in whom repeated injections are less desirable.

The consistent theme across studies is effective, reversible hormone suppression. Because the low-estrogen state has implications such as effects on bone, treatment duration is often limited and managed carefully. The appropriate use and length of therapy are determined by specialists.

Dosing & side effects

Nafarelin is administered as an intranasal spray on a schedule set by the treating clinician, with technique and timing important for consistent absorption. This page does not provide dosing instructions.

Side effects largely reflect the resulting low-estrogen state and may resemble menopausal symptoms, including hot flashes, vaginal dryness, headache, mood changes, reduced libido, and decreased bone mineral density with longer use. Because the spray is nasal, local nasal irritation can also occur. In children, clinicians watch growth and pubertal progression.

As with other GnRH agonists, an early hormonal flare can transiently worsen symptoms before suppression sets in. Due to bone-related considerations, the duration of therapy is often limited, and supportive strategies may be recommended. Patients should discuss monitoring and any nasal congestion concerns, which can affect dosing, with their care team.

Legal status

Nafarelin is an FDA-approved prescription medication and is approved by regulators in other countries as well. It is used under medical supervision, even though it can be self-administered nasally at home.

It is not available over the counter and is not intended for non-medical use. Its approved indications, notably endometriosis and central precocious puberty, are defined by regulatory authorities and product labeling.

Because nafarelin requires appropriate diagnosis, patient selection, and monitoring, especially in children, it should be obtained only through legitimate medical channels and used under a clinician's guidance.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Chrisp P, Goa KL. Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions. Drugs. 1990. Peer-reviewed study
2. Wong JM, Forrest KA, Snabes SZ, et al. Efficacy of nafarelin in assisted reproductive technology: a meta-analysis. Hum Reprod Update. 2001. Peer-reviewed study
3. Minaguchi H, Wong JM, Snabes MC. Clinical use of nafarelin in the treatment of leiomyomas. A review of the literature. J Reprod Med. 2000. Peer-reviewed study
4. Burry KA. Nafarelin in the management of endometriosis: quality of life assessment. Am J Obstet Gynecol. 1992. Peer-reviewed study
5. Barbieri RL. Comparison of the pharmacology of nafarelin and danazol. Am J Obstet Gynecol. 1990. Peer-reviewed study
6. Alizadeh B, Bahari Javan N, Akbari Javar H, et al. Prolonged injectable formulation of Nafarelin using in situ gel combination delivery system. Pharm Dev Technol. 2018. Peer-reviewed study